5 March 2025
Transactions by Persons
Discharging Managerial Responsibilities
AstraZeneca PLC (the Company)
announced that, on 4 March 2025, certain Persons Discharging
Managerial Responsibilities of the Company (PDMRs) were granted
awards of the Company's ordinary shares of $0.25 each (Ordinary
Shares) under the terms of the AstraZeneca Deferred Bonus Plan
(AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as
detailed in the table below.
|
PDMR
|
Position
|
Ordinary Shares granted under the AZDBP
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
|
Pascal Soriot
|
Executive Director and Chief Executive
Officer
|
14,623
|
109,781
|
£119.63
|
|
Aradhana Sarin
|
Executive Director and Chief Financial
Officer
|
6,243
|
45,494
|
£119.63
|
The AZDBP award represents the
portion of each PDMR's annual bonus for 2024 that they are required
to defer into shares. The Ordinary Shares granted under the AZDBP
are subject to a three-year holding period and are due to vest on
the third anniversary of grant.
The AZPSP award is subject to a
combination of performance measures focused on scientific,
commercial, financial and sustainability performance. The
performance measures will be assessed over a three-year performance
period (1 January 2025 to 31 December 2027). The Ordinary Shares
granted under the AZPSP are subject to a two-year holding period
following the performance period, and are due to vest on the fifth
anniversary of grant.
Details of the performance measures
attached to the AZPSP award can be found in the Directors'
Remuneration Report within the AstraZeneca Annual Report and Form
20-F Information 2024, which is available on the Company's website
at
www.astrazeneca.com/annualreport2024.
Further details are set out in the attached
notification, made in accordance with the requirements of the EU
Market Abuse Regulation (as it forms part of UK law pursuant to the
European Union (Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Pascal Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in
AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the
AstraZeneca Performance Share Plan and the AstraZeneca Deferred
Bonus Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£119.63
|
124,404
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single
transaction
|
|
e)
|
Date of the transaction
|
4 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Aradhana Sarin
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in
AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the
AstraZeneca Performance Share Plan and the AstraZeneca Deferred
Bonus Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£119.63
|
51,737
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single
transaction
|
|
e)
|
Date of the transaction
|
4 March 2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is
a global, science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
